SARS-CoV-2 infection in Ivory Coast: a serosurveillance survey among gold mine workers

4

1

Jean Marie Milleliri¹, Daouda Coulibaly², Blaise Nyobe³, Jean-Loup Rey¹,
Franck Lamontagne¹, Laurent Hocqueloux⁴, Susanna Giaché⁴, Antoine Valery⁵,
Thierry Prazuck⁴*

8

9 1: Groupe d'intervention en sante publique et epidemiologie, Marseille, France,
10 2: Institut National de sante publique, Abidjan, Cote d'Ivoire; 3: Medicis,
11 Urgences, Abidjan, Cote d'Ivoire, 4: Maladies infectieuses et tropicales, Centre
12 Hospitalier Regional d'Orleans, France; 5: Departement d'information
13 medicale, Centre Hospitalier Regional d'Orleans, France

14

*: Corresponding author: Thierry Prazuck, Centre Hospitalier Regional
 d'Orleans, 14 avenue de l'hopital, 45067 Orleans, Cedex 2, France .
 <u>thierry.prazuck@chr-orleans.fr</u>, phone: 00(33) 238229593

18

19 Key words : Sars-Cov2 ; epidemiology, Africa, Ivory Coast; prevalence

20

22

21 Abstract: 189 words; manuscript: 2229 words

- 23 2 tables
- 24

Background: Eight months after the detection of the first COVID-19 case in Africa, 1,262,476 cases have been reported in African countries compared to 72 million worldwide. The real burden of SARS-CoV-2 infection in West Africa is not clearly defined. The aim of the study was to evaluate the seroprevalence of SARS-CoV-2 in half of the 3,380 workers of several mining companies operating in two mines in the Ivory Coast and having its headquarters in the economic capital Abidjan.

Methods: From 15th July to 13th October 2020, a voluntary serological test campaign was performed in the 3 sites where the companies operate: two mines, and the headquarters in Abidjan.We performed a COVID-PRESTO rapid test for the detection of IgG and IgM on capillary blood. A multivariate analysis was performed to identify independent sociodemographic characteristics associated with a higher SARS-CoV-2 seroprevalence rate.

Results: A total of 1,687 subjects were tested. 91% were male (n= 1,536)

and mean age was 37 years old. The overall crude seroprevalence rate was
 25.1% (n=422), but differing significantly between different sites, rising

41 from 13.6% (11.2%-16.1%) in mine A to 34.4% (31.1%-37.7%) in mine B

42 and 34.7% (26.2%-43.2%) in Abidjan. Non-resident workers in mines had a

43 significantly lower prevalence rate than those living full-time in mines.

Seroprevalence was 26.5% in natives of the Ivory Coast, while people coming from countries other than Africa were less likely to be SARS-CoV-2 seropositive. Among the 422 positive subjects, 74 reported mild symptoms in the three previous months and one was hospitalized for a severe COVID-19 infection. **Conclusion**: The prevalence of SARS-CoV-2 infection among mine workers in Ivory Coast is high. The low morbidity observed has probably led to an underestimation of the burden of this infection in West Africa. The high prevalence reported in subjects living in Abidjan, who have not any close contact with mine workers, may be indicative of the real seroprevalence in the Ivory Coast capital.

CoronaVirus Disease 2019 (COVID-19) represents an unprecedented international public health challenge responsible for significant morbidity and mortality. In March 2020, the World Health Organization (WHO) officially declared the COVID-19 pandemic. As of 17th December 2020, the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) caused 1,637,000 deaths out of more than 72 million cases reported worldwide. Unfortunately these numbers continue to increase every day¹.

Officially, according to the latest October 21st 2020 WHO report, COVID-19
cases in Africa were 1,262,476 and COVID-19 related deaths were 28,601,
with no significant change in incidence over weeks (29,919 new confirmed
cases and 474 new deaths from 46 countries, compared to 30,145 cases and
747 deaths in the previous week)².

Considering the daily increase in the number of COVID-19 cases all around 84 85 the world, it appears that Africa is controlling the epidemic spread better than Europe, United States or South America. Catastrophic scenarios about 86 87 potentially devastating effect of COVID-19 in Africa have fortunately not yet occurred. The reasons are multiple and not always clearly established³. 88 Some authors argue that this epidemic reached Africa a few weeks after 89 90 Europe and African leaders adopted preventive measures thanks to acquired knowledge of what was happening in Europe, having probably 91 92 learned important lessons from previous major outbreaks, like 2014 Ebola

93 virus disease in West Africa. In addition, many parts of Africa are still isolated and not linked to significant tourism and international business 94 95 related traffic. However, according to recent data, SARS-CoV-2 serological positivity in South Africa appears to be so high that it approaches the herd 96 immunity threshold (i.e. more than 60%) (Jonny Myers, Maverick Citizen, 97 Open Edition, 7 oct 2020)⁴. Did SARS-CoV2 infection largely and silently 98 spread in Africa, or did factors such as environment, younger population, 99 100 climate and policies limit the penetration of the virus in most African countries? 101

102 Since March 2020, Ivory Coast, Mali and Burkina Faso have faced the SARS-

103 CoV-2 outbreak almost simultaneously. In this report, we present the results of a COVID-19 serological testing campaign conducted in Ivory Coast 104 among employees of a gold mining company using a reliable rapid Point-of-105 Care (POC) antibody test.

107

106

Background 108

Several mining companies operate in West Africa. Occupational Health 109 department is in charge of mine workers as well as administrative staff. 110 111 Mines are mainly located in rural areas of the country, between 200 km and 500 km far from the economic capital of the country (Abidian) where these 112 113 companies' headquarters are located. Three-thousand three hundred and

medRxiv preprint doi: https://doi.org/10.1101/2021.01.27.21249186; this version posted January 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

eighty people are currently working in these sites, including the Abidjan 114 headquarters. Of these 3,380 workers, 1,360 are direct employees and 115 2,020 are subcontractor's employees of different companies. Direct 116 employees working in the mines live on site in a rather confined place, 117 while the subcontractor's employees come back home in their 118 villages/towns every day. Administrative staff and other workers located in 119 Abidjan headquarters are mainly exposed to COVID-19 in their daily 120 121 activities in contact with the Ivorian urban population of Abidjan. The objective of this testing campaign was to sensitize and protect employees 122 123 and their families, particularly when a recent SARS-CoV-2 infection was 124 diagnosed.

125

126 Subjects and methods

The serological screening based on voluntary testing was conducted in the 127 period between July 15th and October 13th. All employees were informed 128 about the objectives of the campaign and were invited to participate. No 129 clinical criteria were required to be tested. Tests were performed at the 130 different work sites by healthcare personnel according 131 to the manufacturers' instructions after a two-hours training session. For each 132 participant, a written informed consent was obtained. Test result was 133 provided within 15 minutes. A photograph of each cassette was 134

systematically performed to be assessed by an independent operator. A
standardized questionnaire was filled for each subject, including age, sex,
working status and previous symptoms potentially related to a SARS-CoV-2
infection in the previous five months (i.e. fever, dyspnea, cough, flu-like
syndrome, anosmia/ageusia).

140

141 *Point-of-care used test*

The COVID-PRESTO® SARS-CoV-2 IgG/IgM antibody test kit is a lateral 142 flow immune-chromatographic assay targeting antibodies specific to the 143 SARS-CoV-2 N-protein. It has been manufactured and marketed by AAZ-144 LMB and already approved by French authorities. This rapid diagnostic test 145 (RDT) uses anti-human IgM antibodies (test line IgM), anti-human IgG 146 antibodies (test line IgG) and rabbit IgG (control line C) immobilized on a 147 nitrocellulose strip. The Conjugate (recombinant SARS-CoV-2 antigens 148 149 labeled with colloidal gold) is also integrated into the strip. When a specimen is well placed in the sample and the assay buffer is added, the IgM 150 and IgG antibodies, if present, bind to the SARS-CoV-2 conjugates forming 151 antigen-antibodies complex. This complex migrates through a 152 an nitrocellulose membrane by capillary action. When the complex meets the 153 154 line of the corresponding immobilized antibodies (anti-human IgM and/or anti-human IgG), the complex is trapped and form a burgundy-colored band 155

156 confirming test result. Results must be read within 10 minutes by two independent operators. When the control line is the only one present, the 157 158 sample is negative. If the control line does not appear, the test is invalid and should be repeated with a new cassette. Performances of this test have 159 already been assessed in real life, regardless of the manufacturer's 160 instructions. The sensitivity of COVID-PRESTO® test ranged from 10% for 161 patients having experienced their first symptoms from 0 to 5 days earlier to 162 163 100% in patients whose symptoms occurred more than 15 days earlier⁵.

164

165 Statistical analysis

Data were collected on an Excel spreadsheet. Data were categorized by 166 mine site, sex, age and working characteristics (i.e. direct employees vs 167 subcontractor's employees). Qualitative and quantitative 168 variables including the proportion of seropositivity were reported in percentage and 169 170 a 95% confidence interval. Multivariate logistic regression was used to determine the relationship between demographics characteristics and 171 seropositivity to the SARS-CoV-2. A p value of less than 0.05 was regarded 172 173 as statistically significant. Only statistically significant variables were introduced in the multivariate model. Analysis was carried out using R 174 studio software. 175

177 *Ethical considerations*

The GISPE Research and Ethical committee approved the survey on May
179 15th 2020 (N° EC-GISPE014). Potential participants were informed about
the campaign purpose and procedures.

- 181
- 182 **Results**

Among the 3,380 employees, a total of 1,687 subjects (49.9%) were 183 184 included in the study. One thousand five hundreds thirty-five were male and 151 were female. Mean age was 37 (18-66) years old; 1,566 employees 185 (92.7%) worked in the mine sites and 121 (7.3%) in Abidjan. Among 186 mining workers, 845 were direct employees living night and day in the 187 compound (587 in mine A and 258 in mine B), and 718 were 188 subcontractor's employees of other companies working in the mine during 189 the day but coming back to village after work (213 in mine A and 501 in 190 191 mine B). One thousand four hundreds fifty-eight workers were native from Ivory Coast (86.4%), 143 from another African country (8.5%) and the 192 remaining 87 (5.1%) came from 12 worldwide countries (Details in Table I) 193 194 Subjects working in Abidjan were significantly older (63% over 36 years old) and the proportion of male workers was half compared to mine sites. 195 196 Among the 1,687 people included in the study, 422 had a positive serological test (either IgG and/or IgM). Overall seroprevalence was 25.1% 197

198 and prevalence rates were similar when stratified by age or gender. According to the different working sites, the seroprevalence was 34.4%, 199 34.7%, and 13.6% in mine A, Abidjan headquarters and mine B. 200 Seroprevalence rate was significantly lower in subcontractors workers than 201 in those living full time in the mines. Ivory Coast natives had the highest 202 prevalence rate [26.5% (24.3% - 28.8%)]. Conversely, people coming from 203 countries outside Africa were less likely to be SARS-CoV-2 seropositive 204 205 (Details in Table 2).

Among the 422 seropositive subjects, only one had previously been hospitalized for a suspected COVID-19. Eighteen additional subjects had mild symptoms and were diagnosed by a positive real-time reverse transcription polymerase chain reaction (RT-PCR) test. Among the 404 remaining subjects, 74 reported mild nonspecific symptoms that may or may not be attributable to a SARS-CoV-2 infection, particularly in a tropical setting, but were not tested at the time of symptoms.

213

214 **Discussion**

The current epidemiological study conducted on a specific African population reports a SARS-CoV-2 seroprevalence as high as 35% in gold mining workers as well as in administrative staff living in Abidjan. This high seroprevalence rate has been reached before July 2020, and it

219 remained stable after the first pandemic wave, between July and October
220 2020. This silent outbreak had not previously been detected because most
221 cases were asymptomatic.

From March to December 1st, 2020, Ivory Coast reported 21,250 SARS-CoV-222 2 infections and 127 COVID-19 related deaths, meaning that only the 223 0.084% of Ivory Coast's 25 million inhabitants has been infected ². Official 224 available data do not reflect the burden of infection but may reflect the 225 226 emerging part of the iceberg. To our knowledge, there are very few published studies evaluating SARS-CoV-2 seroprevalence in African 227 228 countries. In Togo, among 955 participants from five different sectors, the prevalence rate was 0.9% (95% CI: 0.4%-1.8%)⁶. In a study conducted in 229 Kenya from April to June 2020 on 3,174 blood donors' samples, 230 seroprevalence was 5.2% (95%CI: 3.7%-7.1%)⁷. In two small populations 231 232 of household contacts and healthcare workers in Nigeria, seroprevalence rates rise to 25.4% and 45% respectively ^{8,9}. Among the available pre-print 233 or published studies, seroprevalence was evaluated using Rapid Diagnostic 234 Tests (RDTs) in three studies, enzyme-linked immunosorbent assay (ELISA) 235 in three studies and Clinical Laboratory Improvement Amendments (CLIA) 236 in one study⁶⁻¹². A recent study aiming to detect the persistence of SARS-237 CoV-2 antibodies 3 to 4 months after the onset of symptoms in healthcare 238 239 workers at the Strasbourg University hospital reported that ELISA

240 serological test has a 59% sensitivity and Biosynex RDT a 85% sensitivity compared to the S-flow reference test developed by the French National 241 Reference Center for SARS-CoV-2 infection (Pasteur Institute, Paris, 242 France)¹³. The RDT used in our study showed high sensitivity even more 243 than 21 days after onset of symptoms, as well as a 100% specificity in a 244 study carried out independently from the manufacturer¹⁴. Hence, 245 seroprevalence rates from studies using ELISA tests must be cautiously 246 247 interpreted as they may underestimate the real data.

In our study, 14% to 35% of workers were SARS-CoV-2 seropositive, 248 249 despite having no symptoms or at least no severe disease. These data appear to be quite different than that observed in the rest of the world, but 250 similar results have already been described in Ibadan, Nigeria, in healthcare 251 workers who are much more exposed to the infection than mine workers ⁹. 252 253 A high level of seropositivity was found in both mining workers and administrative staff living in the economic capital. In mine A, as people live 254 together, a cluster phenomenon may have occurred, explaining the 255 difference in seroprevalence with mine B, which was more confined during 256 the first wave with limited circulation between mine B and Abidjan. 257 258 Subjects living in mine B had the same life habits as the African population living in Abidjan. Therefore, we can expect that this similar seroprevalence 259 260 reflects the real one in Abidjan.

In mine B, subcontractors' workers constitute 67% of the working population compared to 29% in mine A. As subcontractors' worker do not live full-time in the mine, the lower seroprevalence of this population, could reflect a lower prevalence in rural areas of the country.

In the capital, seropositivity was 34.7% among the 121 subjects working in
the administrative staff in Abidjan and having no contact with gold mines.
This data could reflect the high SARS-CoV-2 seroprevalence in the general
population living in Abidjan.

Nevertheless, the most surprising results of the current study are the 269 270 extremely low percentage of symptomatic cases and mortality rate. Some 271 authors speculate that African SARS-CoV-2 seroprevalence data could be related to a younger population, a favorable climate and possible 272 preexisting immunity due to previous exposure to other coronaviruses ¹⁴. 273 274 In our study, mean age was 37 years old and there was no increase in symptoms incidence or hospitalization according to age range. Our 275 prevalence rates do not support hypothesis of a previous cross-reacting 276 immunity due to other coronaviruses. 277

278 Relatively stable prevalence rates observed between July and September 279 may indicate that SARS-CoV-2 outbreak occurred as early as March or April 280 as in Europe, mainly not to say exclusively from imported cases, and spread 281 silently but rapidly across the country. The plateau observed since July

could be related either to complete travel restrictions, to the end of the first
epidemic wave as in Europe, to the nationwide control of the SARS-CoV-2
circulation, or may reflect other phenomena including pre-existing
immunity, genetic factors ... in the remaining population.

286

287 This study has some limitations. Firstly, the included population is not representative of the general Ivoirian population, although subjects living 288 in Abidjan have similar habits to those of the Abidjan's population. 289 Furthermore, the voluntary test may have selected people thinking to be 290 more exposed to the virus, for example people who previously had mild 291 symptoms or had households contacts of a confirmed SARS-CoV-2 case. 292 Third, even if COVID-PRESTO® has an excellent diagnostic performance, 293 diagnostic sensitivity decreases a few months after the infection, compared 294 to the reference test S-Flow, and may therefore have underestimated the 295 296 real seroprevalence.

297

In conclusion, the high SARS-CoV-2 prevalence rate among mining workers recruited for this study confirms a higher proportion of asymptomatic cases than that observed in Europe, South America or United States of America till now. Herd immunity could be achieved in Africa much easier than expected without generating a dramatic health crisis.

*: Corresponding author: Thierry Prazuck, Service des maladies infectieuses						
et tropicales, Centre Hospitalier Regional d'Orleans, 14 avenue de l'hopital,						
450	67 Orleans, Cedex 2, France . <u>thierry.prazuck@chr-orleans.fr</u> , phone:					
00(33) 238229593					
Refe	erences:					
1.	WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cité 17					
	déc 2020]. Disponible sur: https://covid19.who.int/table					
2.	COVID-19 Situation update for the WHO African Region, External					
	Situation Report 34 (21 October 2020) - South Africa [Internet].					
	ReliefWeb. [cité 17 déc 2020]. Available at:					
	https://apps.who.int/iris/bitstream/handle/10665/336181/SITREP_C					
	OVID-19_WHOAFRO_20201021-eng.pdf					
3.	Payne C. COVID-19 in Africa. Nat Hum Behav. mai 2020;4(5):436-7.					
4.	Myers J. MAVERICK CITIZEN OP-ED: Covid-19: After a severe epidemic,					
	South Africa appears to be approaching some herd immunity [Internet].					
	Daily Maverick. 2020 [cité 17 déc 2020]. Disponible sur:					
	et t: 450 00(1 Refe 1. 2. 3.					

322		https://www.dailymaverick.co.za/article/2020-10-07-covid-19-after-
323		a-severe-epidemic-south-africa-appears-to-be-approaching-some-
324		herd-immunity/
325	5.	Prazuck T, Colin M, Giachè S, Gubavu C, Seve A, Rzepecki V, et al.
326		Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined
327		antibody tests on capillary whole blood samples from the fingertip.
328		PLoS One. 2020;15(9):e0237694.
329	6.	Halatoko WA, Konu YR, Gbeasor-Komlanvi FA, Sadio AJ, Tchankoni MK,
330		Komlanvi KS, et al. Prevalence of SARS-CoV-2 among high-risk
331		populations in Lomé (Togo) in 2020. PLoS One. 2020;15(11):e0242124.
332	7.	Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al.
333		Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood
334		donors. medRxiv. 29 juill 2020;2020.07.27.20162693.
335	8.	Asuquo MI, Effa E, Otu A, Ita O, Udoh U, Umoh V, et al. Prevalence of IgG
336		and IgM antibodies to SARS-CoV-2 among clinic staff and patients.
337		medRxiv. 24 juill 2020;2020.07.02.20145441.
338	9.	Olayanju O, Bamidele O, Edem F, Eseile B, Amoo A, Nwaokenye J, et al.
339		SARS-CoV-2 Seropositivity in Asymptomatic Frontline Health Workers
340		in Ibadan, Nigeria. Am J Trop Med Hyg. 11 nov 2020;

341	10.	Majiya H, Aliyu-Paiko M, Balogu VT, Musa DA, Salihu IM, Kawu AA, et al.
342		Seroprevalence of COVID-19 in Niger State. medRxiv. 5 août
343		2020;2020.08.04.20168112.
344	11.	Kempen JH, Abashawl A, Suga HK, Nigussie Difabachew M, Kempen CJ,
345		Tesfaye Debele M, et al. SARS-CoV-2 Serosurvey in Addis Ababa,
346		Ethiopia. Am J Trop Med Hyg. nov 2020;103(5):2022-3.
347	12.	Chibwana MG, Jere KC, Kamng'ona R, Mandolo J, Katunga-Phiri V,
348		Tembo D, et al. High SARS-CoV-2 seroprevalence in Health Care
349		Workers but relatively low numbers of deaths in urban Malawi.
350		medRxiv. 1 août 2020;
351	13.	Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, et
352		al. Sex differences in the decline of neutralizing antibodies to SARS-
353		CoV-2. medRxiv. 15 nov 2020;2020.11.12.20230466.
354	14.	Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M, et al. Why
355		is There Low Morbidity and Mortality of COVID-19 in Africa? Am J Trop
356		Med Hyg. ao2020;103(2):564-9.
357		

362
363
364

Characteristics	Overall	Ity	Agbaou	Abidjan	p
N	1687	803	763	121	
Sex ratio (M/F)	10.2	14.1	10.1	3.17	< 0.001
Age Mean (SD) • <36 • 36-49 • >=50	38 (8.6) 805 733 149	36 (8.3) 400 338 65	37 (8.7) 359 336 68	39 (9.7) 46 59 16	0.001 NS
 Employee's status Direct employees Subcontractors Administrative staff 	848 721 118	587 213 3	258 505	3 3 115	<0.001

376 Table I: Sociodemographic characteristics of the study population

			Univariate			Multivariate	
		N	Prevalence [95% CI]	OR	Р	aOR (95% CI)	Р
Gender	Female Male		25,2% [18,2%-32,1%] 25% [22,8%-27,2%]	1,01 [0,94-1,09] 0,99 [0,92-1,07]	NS	0,88 [0,58-1,3] 1	NS

Age ≤35 36-49 ≥50	805 733 149	24,8% [21,9%-27,8%] 25,2% [22,1%-28,4%] 24,8% [17,9%-31,8%]	0,98 [0,96-1,01] 1,02 [1-1,05] 0,99 [0,92-1,07]	NS	1 1,04[0,82-1,33] 1,18[0,75-1,82]	NS NS
Employees status Direct emplyees Subcontractors Administrative staff	848 721 118	33,3% [30,1%-36,4%] 13,7% [11,2%-16,2%] 34,7% [26,2%-43,3%]	2,49 [2,4-2,56] 0,32 [0,3-0,33] 1,66 [1,53-1,8]	< 0.001 ***	2,33 [1,8-3,1] 1 1,58 [0,34-6,8]	0.001** NS
Country of origin Ivory Coast African other Non-African	1458 143 86	26,5% [24,3%-28,8%] 16,1% [10,1%-22,1%] 14% [6,6%-21,3%]	2 [1,86-2,15] 0,55 [0,5-0,6] 0,47 [0,4-0,57]	0.001 **	3.5 [1,9-7] 1,8 [0,9-4.2] 1	0.001* NS
Location Mine A Mine B Abidjan	803 763 121	34,4% [31,1%-37,7%] 13,6% [11,2%-16,1%] 34,7% [26,2%-43,2%]	2,65 [2,58-2,72] 0,3 [0,3-0,3] 1,66 [1,53-1,8]	< 0.001 ***	2,54 [1,9-3,35] 1 3,5 [0,8-16,4]	<0.001*** NS

382 Table II: SarS-CoV2 seroprevalence rates, odds ratios and 95% confidence

interval according to sociodemographic characteristics plus adjusted oddsratio (logistic model).